Ramin Farzaneh-Far is Chief Medical Officer at Ra Pharmaceuticals, Inc. (RARX). They have made 14 open-market trades across 1 company since 2019, most recently 2020-04-02.
CIK 0001688195
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 14 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RARX | 7,132 | $342K |
Shares reported on the most recent Form 4, priced at the 2020-03-18 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RARX | SELL | 2020-03-16 | 2020-03-18 | $45.16 | $957K | +16.9% | N/A | N/A |
| RARX | SELL | 2020-02-18 | 2020-02-20 | $46.61 | $988K | +0.3% | -3.0% | N/A |
| RARX | SELL | 2020-01-15 | 2020-01-16 | $46.95 | $995K | +0.1% | -0.6% | N/A |
| RARX | SELL | 2019-12-16 | 2019-12-18 | $47.23 | $500K | +0.0% | +0.1% | -4.6% |
| RARX | SELL | 2019-12-16 | 2019-12-18 | $47.23 | $1.0M | +0.0% | +0.1% | -4.6% |
| RARX | SELL | 2019-11-15 | 2019-11-18 | $46.66 | $989K | +0.0% | +0.4% | +0.0% |
| RARX | SELL | 2019-10-15 | 2019-10-17 | $46.89 | $994K | -0.2% | +0.0% | +0.6% |
| RARX | SELL | 2019-09-16 | 2019-09-16 | $25.26 | $268K | +0.6% | +88.4% | +90.2% |
| RARX | SELL | 2019-09-16 | 2019-09-16 | $25.26 | $535K | +0.6% | +88.4% | +90.2% |
| RARX | SELL | 2019-08-23 | 2019-08-27 | $27.77 | $588K | -8.2% | -8.9% | +70.8% |
| RARX | SELL | 2019-07-15 | 2019-07-16 | $33.10 | $701K | +7.9% | -14.1% | +40.4% |
| RARX | SELL | 2019-07-15 | 2019-07-16 | $33.10 | $351K | +7.9% | -14.1% | +40.4% |
| RARX | SELL | 2019-06-17 | 2019-06-19 | $21.84 | $231K | +36.6% | +38.4% | +5.7% |
| RARX | SELL | 2019-06-17 | 2019-06-19 | $21.84 | $463K | +36.6% | +38.4% | +5.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.